# ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct06460298/  
OnCo record `nct06460298` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ProAgio Dose Levels (DL) 1,2,3,4 in triple-negative breast cancer, run by ProDa BioTech, LLC, now recruiting.

## Summary

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT06460298 by ProDa BioTech, LLC, with 51 participants planned, started 2024-08-20 and due to reach its primary completion in 2027-07-01. Interventions recorded: ProAgio Dose Levels (DL) 1,2,3,4 and ProAgio Dose Expansion.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06460298
- Phase: 1/2
- Setting: Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
- Sponsor: ProDa BioTech, LLC
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT06460298: https://clinicaltrials.gov/study/NCT06460298

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)

---
JSON: https://onco.cc/api/v1/entities/nct06460298.json